Diatex, Inc.

Celgene Corporation

Cymabay Therapeutics, Inc.

Euthymics Bioscience, Inc.

Metabolex, Inc.

Pfizer Corporation

Noramco Gmbh

Eric J Hagen

Jason A Hanko

Edward D Daugs

David H Louks

Valeriya N Smolenskaya

Jeffrey Stults

Kevin Halloran

David Alan Engers

Aeri Park

Stuart Dimock

The present invention provides crystalline solid and amorphous forms of (&#x2212;)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (&#x2212;)-halofenate.

Crystalline solid and amorphous forms of (&#x2212;)-halofenate and methods related thereto

The invention provides polymorphic crystalline forms of acid addition salts of (+)-1-(3, 4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane designated as polymorph form A, polymorph form B and polymorph form C, where polymorph form A is more thermodynamically stable than the other forms, methods for preparing and using such polymorph forms and pharmaceutical compositions containing such polymorph forms.

Polymorphs of azabicyclohexane

The present disclosure provides solid forms of a compound of formula I. In some embodiments, the present disclosure provides crystalline forms of Compound I. In some embodiments, the present disclosure provides solvate forms of Compound I. In some embodiments, the present disclosure provides amorphous Compound I.

Romidepsin solid forms and uses thereof

The invention provides polymorphic crystalline forms of acid addition salts of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane designated as polymorph form A, polymorph form B and polymorph form C, where polymorph form A is more thermodynamically stable than the other forms, methods for preparing and using such polymorph forms and pharmaceutical compositions containing such polymorph forms.

Crystalline solid and amorphous forms of (&#x2212;)- halofenate and methods related thereto

The present invention relates to crystalline forms of (3S)-3-[N&#x2014;(N'-(2-tert-butylphenyl)oxamyl)alaninyl]amino-5-(2&#x2032;,3&#x2032;,5&#x2032;,6&#x2032;-tetrafluorophenoxy)-4-oxopentanoic acid (see formula I). The invention further relates to pharmaceutical compositions comprising such crystalline forms and to the use of said pharmaceutical compositions and said crystalline forms in the treatment of various conditions, particularly in the treatment of liver fibrosis. 

Crystalline forms

Hydrocodone bitartrate forms are disclosed which are useful as analgesic agents either in combination with or as replacements for hydrocodone bitartrate.

Growing community of inventors

Lafayette, IN, United States of America

Eric J Hagen